Skip to main content
. 2013 Sep 5;109(7):1997–2004. doi: 10.1038/bjc.2013.546

Table 4. Crude and adjusted OR and 95% CI for the associations between serum 25(OH) vitamin D concentration and risk of death from chronic liver disease in the case–control set nested in the Nutrition Intervention Trials cohort.

 
 Continuousa
 Quartileb
 
  
  
 Q1 (n=266)c
 Q2 (n=265)c
 Q3 (n=266)c
 Q4 (n=265)c
  
  
  OR 95% CI n OR (Reference) n OR 95% CI n OR 95% CI n OR 95% CI Ptrend Pinteraction
Crude 0.88 0.82–0.94 106 1.00 79 0.75 0.53–1.05 56 0.53 0.37–0.76 41 0.39 0.26–0.58 <0.001 —
Age- and sex-adjusted
 0.88
 0.81–0.95
 —
 1.00
 —
 0.75
 0.54–1.05
 —
 0.53
 0.37–0.77
 —
 0.39
 0.26–0.58
 <0.001
 —
Fully adjustedd
 0.86
 0.78–0.93
 —
 1.00
 —
 0.79
 0.55–1.14
 —
 0.50
 0.34–0.75
 —
 0.34
 0.21–0.55
 <0.001
 —
 Women 0.84 0.71–0.99 54 1.00 47 0.95 0.58–1.57 24 0.40 0.22–0.72 17 0.26 0.12–0.52 <0.001 0.710
 Men
 0.86
 0.77–0.96
 52
 1.00
 32
 0.64
 0.37–1.10
 32
 0.58
 0.33–1.01
 24
 0.41
 0.21–0.80
 0.007
  
Age at baseline
<55 0.89 0.78–1.00 50 1.00 37 0.84 0.49–1.45 27 0.49 0.27–0.87 23 0.43 0.22–0.85 0.003 0.459
⩾55
 0.84
 0.74–0.96
 56
 1.00
 42
 0.78
 0.48–1.29
 29
 0.55
 0.32–0.94
 18
 0.29
 0.15–0.58
 <0.001
  
Season of blood draw
January–May 0.81 0.72–0.91 103 1.00 75 0.79 0.55–1.15 49 0.51 0.34–0.77 25 0.40 0.24–0.66 <0.001 0.124
August–September
 0.95
 0.81–1.10
 3
 1.00
 3
 0.47
 0.05–4.42
 7
 0.23
 0.04–1.53
 16
 0.10
 0.02–0.65
 0.004
  
Follow-up years
<7 0.93 0.81–1.08 24 1.00 18 0.75 0.38–1.47 12 0.46 0.22–0.98 17 0.70 0.32–1.53 0.141 0.167
⩾7 to <14 0.77 0.65–0.90 42 1.00 29 0.77 0.45–1.30 25 0.54 0.31–0.95 8 0.13 0.05–0.32 <0.001  
⩾14
 0.88
 0.77–1.01
 40
 1.00
 32
 0.83
 0.49–1.39
 19
 0.43
 0.24–0.79
 16
 0.35
 0.17–0.70
 <0.001
  
HBV/HCV seroposivity
HBV+ 0.87 0.78–0.95 74 1.00 53 0.68 0.46–1.02 44 0.56 0.37–0.86 30 0.34 0.20–0.57 <0.001 0.189
HCV+ 0.98 0.85–1.13 16 1.00 16 1.09 0.52–2.26 7 0.44 0.17–1.09 12 0.80 0.34–1.89 0.240 0.140
Neither
 0.84
 0.70–1.01
 31
 1.00
 19
 0.64
 0.35–1.18
 11
 0.35
 0.17–0.72
 10
 0.32
 0.14–0.73
 0.001
 —
Calcium
<1.485 mmol l−1 0.88 0.77–1.01 47 1.00 33 0.84 0.49–1.44 29 0.67 0.38–1.16 17 0.43 0.22–0.83 0.009 0.365
⩾1.485 mmol l−1
 0.85
 0.75–0.95
 59
 1.00
 46
 0.74
 0.45–1.21
 27
 0.39
 0.22–0.70
 24
 0.28
 0.14–0.56
 <0.001
  
Trial
Dysplasia Trial 0.96 0.82–1.12 3 1.00 3 0.45 0.05–4.23 7 0.23 0.04–1.50 16 0.10 0.02–0.65 0.004 0.155
General Population Trial 0.80 0.70–0.90 103 1.00 76 0.76 0.52–1.10 49 0.47 0.31–0.73 25 0.37 0.22–0.62 <0.001  

Abbreviations: BMI=body mass index; CI= confidence interval; HBcAg=hepatitis B core antigen; HBsAg=hepatitis B surface antigen; HBV=hepatitis B virus; HCsAg=hepatitis C surface antigen; HCV=hepatitis C virus; OR= odds ratio.

a

ORs for continuous vitamin D were scaled to one-half the interquartile range (7.9 nmol l–1).

b

We used sex-specific cutoff values to calculate relative risks. Quartile for women: <11.17, ⩾11.17 to <14.86, ⩾14.86 to <21.80, ⩾21.80 (nmol l–1); and quartile for men: <18.14, ⩾18.14 to <25.33, ⩾25.33 to <38.84, ⩾38.84 (nmol l–1).

c

Number of subjects in the control group.

d

Adjusted for age at baseline, sex, smoking, drinking, BMI, season of blood draw, HBsAg, HBcAg and HCsAg. The bold entries are considered statistically significant.